IL13 and inflammatory bowel disease: Additionally, recent studies on various drug targets in IBD, such as interferon-γ, interleukin (IL)-10, IL-13, IL-17, and chemokine receptor (CCR)-9, have indicated that a single-target therapeutic strategy is not effective in the treatment of IBD [6].